dc.contributor | Universidade de São Paulo (USP) | |
dc.contributor | Universidade Federal de Minas Gerais (UFMG) | |
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2014-05-27T11:30:51Z | |
dc.date.accessioned | 2022-10-05T19:01:40Z | |
dc.date.available | 2014-05-27T11:30:51Z | |
dc.date.available | 2022-10-05T19:01:40Z | |
dc.date.created | 2014-05-27T11:30:51Z | |
dc.date.issued | 2013-10-14 | |
dc.identifier | Revista Brasileira de Psiquiatria, v. 35, n. 3, p. 284-294, 2013. | |
dc.identifier | 1516-4446 | |
dc.identifier | http://hdl.handle.net/11449/76840 | |
dc.identifier | 10.1590/1516-4446-2012-3505 | |
dc.identifier | S1516-4446-2012-3505 | |
dc.identifier | WOS:000326034600015 | |
dc.identifier | 2-s2.0-84885119225 | |
dc.identifier | 2-s2.0-84885119225.pdf | |
dc.identifier | 7964386240653380 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3925715 | |
dc.description.abstract | To present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings. © 2013 Associação Brasileira de Psiquiatria. | |
dc.language | eng | |
dc.relation | Revista Brasileira de Psiquiatria | |
dc.relation | 2.093 | |
dc.relation | 0,803 | |
dc.rights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | Alzheimer's disease | |
dc.subject | Amyloid-β protein | |
dc.subject | Biomarkers | |
dc.subject | Mild cognitive impairment | |
dc.subject | Neuroimaging | |
dc.subject | Tau protein | |
dc.title | Mild cognitive impairment (part 2): Biological markers for diagnosis and prediction of dementia in Alzheimer's disease | |
dc.type | Artigo | |